Prometheus Blood Test Unpatentable, High Court Rules

Law360, New York (March 20, 2012, 12:39 PM EDT) -- The U.S. Supreme Court's decision Tuesday that Prometheus Laboratories Inc.'s blood testing methods are unpatentable because they cover only laws of nature was hailed by medical professionals but dismayed the biotechnology industry, which said it would hinder the field of personalized medicine.

In a unanimous decision written by Justice Stephen Breyer, the high court reversed a Federal Circuit ruling that the test covered by two Prometheus patents was patentable because it transforms blood taken from the body to determine the proper dosage of thiopurine drugs to...
To view the full article, register now.